Related Experiment Video

Updated: May 14, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Monoclonal antibodies therapies for ovarian cancer

Umberto Leone Roberti Maggiore1, Filippo Bellati, Ilary Ruscito

  • 1University of Genoa, San Martino Hospital and National Institute for Cancer Research, Department of Obstetrics and Gynecology, Largo R. Benzi 1, 16132 Genoa, Italy.

Expert Opinion on Biological Therapy
|February 5, 2013
PubMed
Abstract

Insights

Monoclonal antibodies (mAbs) offer new ovarian cancer (OC) treatment strategies. Bevacizumab shows promise, but further research is needed to define the role of other mAbs and identify biomarkers for personalized OC therapy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Ovarian cancer (OC) patients have a poor prognosis despite current treatments.
  • New management strategies are essential for effective OC treatment.
  • Molecular-targeted agents, including monoclonal antibodies (mAbs), represent a novel therapeutic avenue.

Purpose of the Study:

  • To review the literature on the use of mAbs in ovarian cancer treatment.
  • To explain the mechanisms of action of mAbs.
  • To clarify the current role of mAbs in OC management.

Main Methods:

  • Literature review of monoclonal antibodies (mAbs) in ovarian cancer (OC) treatment.
  • Analysis of existing data on mAb efficacy and mechanisms.
  • Synthesis of information on current and emerging mAb therapies for OC.

Main Results:

  • Bevacizumab has demonstrated significant clinical efficacy in ovarian cancer (OC) treatment.
  • Further clinical trials are required to establish the efficacy of other monoclonal antibodies (mAbs).
  • Understanding OC molecular biology is crucial for developing targeted therapies.

Conclusions:

  • Targeted therapies, particularly monoclonal antibodies (mAbs), are advancing ovarian cancer (OC) treatment.
  • Biomarker identification and validation are critical for patient selection and personalized OC therapy.
  • Ongoing research and larger trials are necessary to optimize mAb use in OC management.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...